Zobrazeno 1 - 10
of 2 786
pro vyhledávání: ''
Autor:
Manon Reda, Pauline Macaire, Hélène Bellio, Lionel Uwer, Silvia Ilie, Véronique Lorgis, Audrey Hennequin, Sylvain Ladoire, Emilie Rederstorff, Pierre Fumoleau, Nicolas Isambert, Nathalie Bonnin, Benoit You, Gilles Freyer, Isabelle Desmoulins, Antonin Schmitt
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:197-208
Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical.This pharmacokinetic/pharmacodynamic (P
Autor:
Anne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Avadhani, Anne O’Hagan, Lilian Y. Li, Daniele Ouellet, Juan Jose Perez Ruixo
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:151-164
Background Exposure–response analyses were conducted to explore the relationship between selected efficacy and safety endpoints and serum phosphate (PO4) concentrations, a potential biomarker of efficacy and safety, in locally advanced or metastati
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM). The clinical pharmacology of elotuzumab [± lenalidomide/dexamethasone (Ld)] was characterized previously.
Autor:
Drew W. Rasco, Amita Patnaik, Kristen McEachern, Sharon Lu, Wei Guo, Lisa Blaydorn, Murali Beeram, Ellie Im, Amy Mirabella, Jasgit C. Sachdev, Hadi Danaee, Glen J. Weiss
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-1) have improved patient outcomes in a broad range of cancers. The objective of this analysis was to evaluate the PK, pharmacodynamics (PDy), and safety of dostarlim
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future pha
Autor:
Shinjiro Sakamoto, Shintaro Miyamoto, Takeshi Masuda, Satoshi Nakao, Toshihito Otani, Noboru Hattori, Taku Nakashima, Hironobu Hamada, Hiroshi Iwamoto, Yasushi Horimasu, Kazunori Fujitaka, Kakuhiro Yamaguchi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:857-865
Cytotoxic chemotherapy-induced lung injury is a fatal complication in patients with lung cancer and interstitial lung disease (ILD). We aimed to evaluate the association between hyperglycemia and this form of lung injury in patients with lung cancer